Moderna and Korea University Partner on mRNA Vaccine for Hantavirus

Korea University's Vaccine Innovation Center announced a partnership with Moderna in July 2024 to develop an mRNA-based vaccine against hantavirus. The collaboration signals the continued expansion of mRNA technology beyond the COVID-19 vaccines that first proved the approach could work in humans at scale.

The partnership brings together Korea University's Vaccine Innovation Center—led by Heejin Cheong and Ok Park—with Moderna Korea's Ji-Young Sohn. Korea University Guro Hospital, which has served as a frontline facility during infectious disease emergencies including MERS and COVID-19, provides the infectious disease expertise and infrastructure.

The Science Behind the Partnership

Research published recently in Nature Communications shows why mRNA might work well for hantavirus. Scientists tested three vaccine approaches in mice: an mRNA formulation, bare DNA, and DNA wrapped in lipid nanoparticles (a microscopic fatty envelope that helps the vaccine reach cells).

The mRNA candidate triggered stronger T-cell responses—the part of your immune system that hunts down infected cells—compared to older inactivated vaccines. The DNA-wrapped version produced more neutralizing antibodies, which block the virus from entering cells. All three nucleic acid approaches generated both immediate and lasting immune responses, and protected mice comparably to traditional vaccines.

This data gives researchers confidence to move the mRNA version forward into human testing alongside Moderna's expertise.

Why Hantavirus, and Why mRNA

Hantavirus causes hemorrhagic fever with renal syndrome, a serious illness that appears mainly in East Asia. There is no effective treatment once someone is infected, so prevention matters. Traditional vaccine manufacturing for hantavirus has been slow and expensive because the virus is complex and requires protection against multiple strains.

mRNA vaccines work differently. Instead of growing virus in labs or using chemically inactivated virus, mRNA instructions tell your own cells how to make a viral protein—the immune system then learns to recognize and fight it. Because you only need the genetic sequence of the virus, development can be faster. Manufacturing can also be distributed and scaled in ways that older vaccine methods cannot easily match, as the COVID-19 response demonstrated.

The broader strategic context here matters. South Korea faced vaccine supply shortages early in the pandemic and has since invested heavily in domestic vaccine development across multiple platforms. A hantavirus vaccine addresses a real regional disease burden while building the country's expertise in mRNA technology. If the partnership succeeds, similar collaborations could follow for other endemic diseases that have not attracted enough commercial interest to justify traditional vaccine manufacturing.

The Partnership Model

What makes this collaboration structured as it is involves a practical division of labor. Korea University brings specialized infectious disease knowledge and a hospital equipped to handle complex viral research. Moderna brings proven mRNA manufacturing methods, experience navigating regulatory approval, and the cold-chain distribution networks it built for COVID-19 vaccines.

This pattern—academic institutions driving early discovery, companies providing manufacturing scale and regulatory pathways—is becoming the standard model for mRNA vaccine development. Smaller research centers rarely have the resources to move a vaccine candidate through all the clinical trials and manufacturing steps required for approval. Established biotech firms do.

What this expansion into endemic regional diseases suggests is a shift in how vaccine innovation works. For decades, pharmaceutical companies focused on pathogens with large global markets or pandemic risk. Hantavirus affects a much smaller population, so the traditional business case was weak. But mRNA's flexible manufacturing and development speed may change the economics. A technology that can be adapted quickly and produced with less fixed infrastructure makes it viable to develop vaccines for diseases that matter locally or regionally, even if they do not command blockbuster sales.

The initiative marks the maturation of mRNA from a pandemic emergency tool into a genuine platform technology—adaptable, relatively rapid, and extensible to diverse infectious disease targets where it was not economically practical to work before.